IMMX - Immix stock slumps ~20% amid interim data for IMX-110 in colorectal cancer

2023-05-03 09:05:24 ET

Immix Biopharma ( NASDAQ: IMMX ) reported early interim data from a phase 1b/2a trial of IMX-110 in combination with Novartis ( NYSE: NVS ) and BeiGene's ( NASDAQ: BGNE ) tislelizumab to treat patients with advanced metastatic colorectal cancer.

In the study, dubbed IMMINENT-01, the lowest dose of IMX-110 in combination with tislelizumab led to a 100% tumor shrinkage at 2-months in the first group of patients (two out of two first evaluable patients), according to the company.

"We are excited to see 100% tumor shrinkage in the very first cohort at the lowest dose of IMX-110 in combination with anti-PD-1 antibody tislelizumab in our ongoing IMMINENT-01 dose escalation trial, especially in patients with advanced colorectal cancer, who have limited treatment options," said ImmixBio CEO Ilya Rachman.

No dose limiting toxicities have been seen in the first group, according to the company.

The main goal of the ongoing study is to find the maximum tolerated dose and recommended phase 2 dose of IMX-110 plus tislelizumab, and to evaluate safety.

The company noted that it is currently enrolling the next higher dose cohort of IMX-110 plus tislelizumab in advanced solid tumors.

IMMX -21.03% to $2.29 premarket

For further details see: